Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
01:05am, Tuesday, 02'nd Jun 2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price
2020 Global Non-Hodgkin Lymphoma Clinical Trial Pipeline Highlights - ResearchAndMarkets.com
12:00am, Tuesday, 02'nd Jun 2020
The
Why Allogene Therapeutics Is Trading Lower Today
03:52pm, Monday, 01'st Jun 2020
Allogene Therapeutics (NASDAQ: ALLO) shares were trading lower on Monday.The company announced it would commence a $450 million offering of its common stock. Raymond James also downgraded the stock fr
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
10:30am, Monday, 01'st Jun 2020
Allogene Therapeutics, Inc. (ALLO), today announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock. In addition, Allogene expects to grant the und
Cancer Summit Presses Toward Treatments in Covid’s Shadow
10:02am, Monday, 01'st Jun 2020
(Bloomberg) -- The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations
Traders Sift Through Virtual Cancer Meeting’s Winners and Losers
02:32pm, Friday, 29'th May 2020
(Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical On
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome.
'Fantastic' dad, 27, dies leaving pregnant partner and young son
05:00am, Friday, 29'th May 2020
Bryce Jones has been hailed as "a fun loving, energetic man who had a real passion for life
Global Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020 - ResearchAndMarkets.com
12:00am, Friday, 29'th May 2020
The
Venture Funding of Drug Startups Down, But Not Out
03:21pm, Thursday, 28'th May 2020
Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...
Moving Average Crossover Alert: Allogene Therapeutics
02:02pm, Wednesday, 27'th May 2020
Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
DOJ Drops Insider Trading Investigation of 3 Senators
09:11am, Wednesday, 27'th May 2020
The DOJ has dropped investigations into stock trades made by Sens. Dianne Feinstein, Kelly Loeffler, and Jim Inhofe in the early weeks of the pandemic.
FBI ends investigation into stock trades made by Feinstein's husband amid coronavirus
12:45am, Wednesday, 27'th May 2020
Federal investigators are no longer investigating stock trades made by Sen. Dianne Feinstein’s husband as the coronavirus pandemic was in its early stages, the California Democrat’s office said Tu
Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
08:30pm, Tuesday, 26'th May 2020
Webinar Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company.
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
